Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
用户7nEFK6amBq5Y
6天前
20
10
已完结
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-10-05 15:40:30 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规